This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The primary aim is to observe the haemostatic efficacy of NovoSevenĀ® treatment during routine practice in German clinics. The observational study observes patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX, acquired haemophilia, congenital FVII deficiency, or Glanzmann's thrombasthenia who have received at least one dose of NovoSevenĀ® for treatment of a bleeding episode or for the prevention of a bleeding when undergoing surgery or an invasive procedure.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of acute bleeding episodes for which haemostasis (defined as stop or significant reduction of bleeding) will be achieved
Timeframe: within 9 hours after initiation of treatment with NovoSevenĀ® or of invasive procedures for which haemostasis will be maintained during the time period of haemostatic coverage with NovoSevenĀ®